Acanthosis Nigricans Clinical Presentation

  • Author: Jason H Miller, MD; Chief Editor: Dirk M Elston, MD   more...
 
Updated: Jul 15, 2010
 

History

Patients usually present with an asymptomatic area of darkening and thickening of the skin. Pruritus occasionally may be present. Lesions begin as hyperpigmented macules and patches and progress to palpable plaques.

In approximately one third of cases of malignant acanthosis nigricans, patients present with skin changes before any signs of cancer. In another one third of cases, the lesions of acanthosis nigricans arise simultaneously with the neoplasm. In the remaining one third of cases, the skin findings manifest sometime after the diagnosis of cancer. Malignant acanthosis nigricans has been reported to appear abruptly and exuberantly and may be associated with a higher rate of pruritus.[1]

Onset may be related to medication or supplement usage.

Next

Physical

Acanthosis nigricans is characterized by symmetrical, hyperpigmented, velvety plaques that may occur in almost any location but most commonly appear on the intertriginous areas of the axilla, groin, and posterior neck. The posterior neck is the most commonly affected site in children.

Acrochordons (skin tags) are often found in and around the affected areas. Occasionally, lesions of acanthosis nigricans may be present on the mucous membranes of the oral cavity, nasal and laryngeal mucosa, and esophagus. The areola of the nipple also may be affected. Eye involvement, including papillomatous lesions on the eyelids and conjunctiva, may occur. Nail changes, such as leukonychia and hyperkeratosis, have been reported.

The lesions of malignant acanthosis nigricans are clinically indistinguishable from benign acanthosis nigricans.

Note the images below.

Brown velvety plaques with skin tags in the axillaBrown velvety plaques with skin tags in the axilla of a patient with acanthosis nigricans. Acanthosis nigricans. Acanthosis nigricans. Acanthosis nigricans, obesity related. Acanthosis nigricans, obesity related. Acanthosis nigricans of the axilla with one skin tAcanthosis nigricans of the axilla with one skin tag.
Previous
Next

Causes

The definitive cause for acanthosis nigricans has not yet been ascertained, although several possibilities have been suggested. Nine types of acanthosis nigricans have been described.

Obesity-associated acanthosis nigricans

Obesity-associated acanthosis nigricans, once labeled pseudo–acanthosis nigricans, is the most common type of acanthosis nigricans. Lesions may appear at any age but are more common in adulthood. The dermatosis is weight dependent, and lesions may completely regress with weight reduction. Insulin resistance is often present in these patients; however, it is not universal.

Obesity-associated acanthosis nigricans may be a marker for higher insulin needs in obese women with gestational diabetes.[15] Acanthosis nigricans has been shown to be a reliable early marker for metabolic syndrome in pediatric patients.[16]

Syndromic acanthosis nigricans

Syndromic acanthosis nigricans is the name given to acanthosis nigricans that is associated with a syndrome. In addition to the widely recognized association of acanthosis nigricans with insulin resistance, acanthosis nigricans has been associated with numerous syndromes (see the Table in Pathophysiology). The type A syndrome and type B syndrome are special examples.

The type A syndrome also is termed the hyperandrogenemia, insulin resistance, and acanthosis nigricans syndrome (HAIR-AN syndrome). This syndrome is often familial, affecting primarily young women (especially black women). It is associated with polycystic ovaries or signs of virilization (eg, hirsutism, clitoral hypertrophy). High plasma testosterone levels are common. The lesions of acanthosis nigricans may arise during infancy and progress rapidly during puberty.

The type B syndrome generally occurs in women who have uncontrolled diabetes mellitus, ovarian hyperandrogenism, or an autoimmune disease such as systemic lupus erythematosus, scleroderma, Sjögren syndrome, or Hashimoto thyroiditis. Circulating antibodies to the insulin receptor may be present. In these patients, the lesions of acanthosis nigricans are of varying severity.

Acral acanthosis nigricans

Acral acanthosis nigricans (acral acanthotic anomaly) occurs in patients who are in otherwise good health. Acral acanthosis nigricans is most common in dark-skinned individuals, especially those of African American or sub-Saharan African descent. The hyperkeratotic velvety lesions are most prominent over the dorsal aspects of the hands and feet, with knuckle hyperpigmentation often most prominent.

Unilateral acanthosis nigricans

Unilateral acanthosis nigricans, sometimes referred to as nevoid acanthosis nigricans, is believed to be inherited as an autosomal dominant trait. Lesions are unilateral in distribution and may become evident during infancy, childhood, or adulthood. Lesions tend to enlarge gradually before stabilizing or regressing. Unilateral acanthosis nigricans lesions may represent a unilateral epidermal nevus.

Generalized acanthosis nigricans

Generalized acanthosis nigricans is rare and has been reported in pediatric patients without underlying systemic disease or malignancy.[17]

Familial acanthosis nigricans

Familial acanthosis nigricans is a rare genodermatosis that seems to be transmitted in an autosomal dominant fashion with variable phenotypic penetrance. The lesions typically begin during early childhood but may manifest at any age. Familial acanthosis nigricans often progresses until puberty, at which time it stabilizes or regresses.

Drug-induced acanthosis nigricans

Drug-induced acanthosis nigricans, although uncommon, may be induced by several medications, including nicotinic acid, insulin, pituitary extract, systemic corticosteroids, and diethylstilbestrol. Nicotinic acid is most widely recognized association, with acanthosis nigricans, developing on abdomen and flexor surfaces and resolving within 4-10 weeks of discontinuation.[1] Rarely, triazinate, oral contraceptives, fusidic acid, and methyltestosterone have also been associated with acanthosis nigricans. Fibroblast growth factor receptor ligands such as palifermin may cause drug-induced acanthosis nigricans.[7]

The lesions of acanthosis nigricans may regress following discontinuation of the offending medication.

Malignant acanthosis nigricans

Malignant acanthosis nigricans, which is associated with internal malignancy, is the most worrisome of the variants of acanthosis nigricans because the underlying neoplasm is often an aggressive cancer (see the Table in Pathophysiology).

Acanthosis nigricans has been reported with many kinds of cancer, but, by far, the most common underlying malignancy is an adenocarcinoma of gastrointestinal origin, usually a gastric adenocarcinoma. In an early study of 191 patients with malignant acanthosis nigricans, 92% had an underlying abdominal cancer, of which 69% were gastric. Another study reported 94 cases of malignant acanthosis nigricans, of which 61% were secondary to a gastric neoplasm.

Malignant acanthosis nigricans in pediatric patients has been described with gastric adenocarcinoma, Wilms tumor, and osteogenic sarcoma.[1]

In 25-50% of cases of malignant acanthosis nigricans, the oral cavity is involved. The tongue and the lips most commonly are affected, with elongation of the filiform papillae on the dorsal and lateral surfaces of the tongue and multiple papillary lesions appearing on the commissures of the lips. Oral lesions of acanthosis nigricans seldom are pigmented.

Tripe palms may show altered dermatoglyphics due to alteration of epidermal rete ridges

Malignant acanthosis nigricans is clinically indistinguishable from the benign forms; however, one must be more suspicious if the lesions arise rapidly, are more extensive, are symptomatic, or are in atypical locations.

Regression of acanthosis nigricans has been seen with treatment of the underlying malignancy, and reappearance may suggest recurrence or metastasis of the primary tumor.

Mixed-type acanthosis nigricans

Mixed-type acanthosis nigricans refers to those situations in which a patient with one of the above types of acanthosis nigricans develops new lesions of a different etiology. An example of this would be an overweight patient with obesity-associated acanthosis nigricans who subsequently develops malignant acanthosis nigricans.

Previous
 
 
Contributor Information and Disclosures
Author

Jason H Miller, MD  Private Practice, Hametz and Picascia Dermatology Associates, Freehold, New Jersey

Jason H Miller, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, American Society for Dermatologic Surgery, and Society for Pediatric Dermatology

Disclosure: Nothing to disclose.

Coauthor(s)

Ronald P Rapini, MD  Josey Professor and Chair, Department of Dermatology, Professor of Pathology, University of Texas Medical School at Houston and MD Anderson Cancer Center

Ronald P Rapini, MD is a member of the following medical societies: American Academy of Dermatology, American Dermatological Association, American Medical Association, American Society for Dermatologic Surgery, American Society for MOHS Surgery, Society for Investigative Dermatology, and Texas Medical Association

Disclosure: Elsevier publishers Royalty Independent contractor

Specialty Editor Board

Ponciano D Cruz Jr, MD  Vice-Chair, JB Shelmire Professor, Department of Dermatology, University of Texas Southwestern Medical Center

Ponciano D Cruz Jr, MD is a member of the following medical societies: Texas Medical Association

Disclosure: RCTS Consulting fee Independent contractor; Mary Kay Cosmetics Honoraria Consulting; Galderma Grant/research funds Principal Investigator

Michael J Wells, MD  Associate Professor, Department of Dermatology, Texas Tech University Health Sciences Center, Paul L Foster School of Medicine

Michael J Wells, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, and Texas Medical Association

Disclosure: Nothing to disclose.

Edward F Chan, MD  Clinical Assistant Professor, Department of Dermatology, University of Pennsylvania School of Medicine

Edward F Chan, MD is a member of the following medical societies: American Academy of Dermatology, American Society of Dermatopathology, and Society for Investigative Dermatology

Disclosure: Nothing to disclose.

Catherine M Quirk, MD  Clinical Assistant Professor, Department of Dermatology, University of Pennsylvania

Catherine M Quirk, MD is a member of the following medical societies: Alpha Omega Alpha and American Academy of Dermatology

Disclosure: Nothing to disclose.

Chief Editor

Dirk M Elston, MD  Director, Ackerman Academy of Dermatopathology, New York

Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

Additional Contributors

The authors and editors of eMedicine gratefully acknowledge the contributions of previous authors, Jonathan Baron, MD, and Norman Levine, MD, to the development and writing of this article.

References
  1. Sinha S, Schwartz RA. Juvenile acanthosis nigricans. J Am Acad Dermatol. Sep 2007;57(3):502-8. [Medline].

  2. Higgins SP, Freemark M, Prose NS. Acanthosis nigricans: a practical approach to evaluation and management. Dermatol Online J. Sep 15 2008;14(9):2. [Medline].

  3. Berk DR, Spector EB, Bayliss SJ. Familial acanthosis nigricans due to K650T FGFR3 mutation. Arch Dermatol. Sep 2007;143(9):1153-6. [Medline].

  4. Sharda S, Panigrahi I, Gupta K, Singhi S, Kumar R. A newborn with acanthosis nigricans: can it be Crouzon syndrome with acanthosis nigricans?. Pediatr Dermatol. Jan 1 2010;27(1):43-7. [Medline].

  5. Krawczyk M, Mykala-Ciesla J, Kolodziej-Jaskula A. Acanthosis nigricans as a paraneoplastic syndrome. Case reports and review of literature. Pol Arch Med Wewn. Mar 2009;119(3):180-3. [Medline].

  6. Mailler-Savage EA, Adams BB. Exogenous insulin-derived Acanthosis nigricans. Arch Dermatol. Jan 2008;144(1):126-7. [Medline].

  7. Lane SW, Manoharan S, Mollee PN. Palifermin-induced acanthosis nigricans. Intern Med J. Jun 2007;37(6):417-8. [Medline].

  8. Wu JC, Cunningham BB. Ectopic acanthosis nigricans occurring in a child after syndactyly repair. Cutis. Jan 2008;81(1):22-4. [Medline].

  9. Sadeghian G, Ziaie H, Amini M, Ali Nilfroushzadeh M. Evaluation of insulin resistance in obese women with and without acanthosis nigricans. J Dermatol. Apr 2009;36(4):209-12. [Medline].

  10. Scott AT, Metzig AM, Hames RK, Schwarzenberg SJ, Dengel DR, Biltz GR. Acanthosis nigricans and oral glucose tolerance in obese children. Clin Pediatr (Phila). Jan 2010;49(1):69-71. [Medline].

  11. Brickman WJ, Huang J, Silverman BL, Metzger BE. Acanthosis nigricans identifies youth at high risk for metabolic abnormalities. J Pediatr. Jan 2010;156(1):87-92. [Medline].

  12. Stoddart ML, Blevins KS, Lee ET, Wang W, Blackett PR. Association of acanthosis nigricans with hyperinsulinemia compared with other selected risk factors for type 2 diabetes in Cherokee Indians: the Cherokee Diabetes Study. Diabetes Care. Jun 2002;25(6):1009-14. [Medline].

  13. Brickman WJ, Binns HJ, Jovanovic BD, Kolesky S, Mancini AJ, Metzger BE. Acanthosis nigricans: a common finding in overweight youth. Pediatr Dermatol. Nov-Dec 2007;24(6):601-6. [Medline].

  14. Otto DE, Wang X, Tijerina SL, Reyna ME, Farooqi MI, Shelton ML. A Comparison of Blood Pressure, Body Mass Index, and Acanthosis Nigricans in School-Age Children. J Sch Nurs. Mar 24 2010;[Medline].

  15. Daitchman J, Vermeulen MJ, Ray JG. Acanthosis nigricans among women with gestational diabetes mellitus and risk of adverse pregnancy outcomes. Diabetes Care. May 2008;31(5):e30. [Medline].

  16. Ice CL, Murphy E, Minor VE, Neal WA. Metabolic syndrome in fifth grade children with acanthosis nigricans: results from the CARDIAC project. World J Pediatr. Feb 2009;5(1):23-30. [Medline].

  17. Gönül M, Kiliç A, Cakmak SK, Gül U, Ekiz OD, Ergül G. Juvenile generalized acanthosis nigricans without any systemic disease. Pediatr Int. Aug 2009;51(4):595-7. [Medline].

  18. Coates P, Shuttleworth D, Rees A. Resolution of nicotinic acid-induced acanthosis nigricans by substitution of an analogue (acipimox) in a patient with type V hyperlipidaemia. Br J Dermatol. Apr 1992;126(4):412-4. [Medline].

  19. Sherertz EF. Improved acanthosis nigricans with lipodystrophic diabetes during dietary fish oil supplementation. Arch Dermatol. Jul 1988;124(7):1094-6. [Medline].

  20. Adigun CG, Pandya AG. Improvement of idiopathic acanthosis nigricans with a triple combination depigmenting cream. J Eur Acad Dermatol Venereol. Apr 2009;23(4):486-7. [Medline].

  21. Mork NJ, Rajka G, Halse J. Treatment of acanthosis nigricans with etretinate (Tigason) in a patient with Lawrence-Seip syndrome (generalized lipodystrophy). Acta Derm Venereol. 1986;66(2):173-4. [Medline].

  22. Darmstadt GL, Yokel BK, Horn TD. Treatment of acanthosis nigricans with tretinoin. Arch Dermatol. Aug 1991;127(8):1139-40. [Medline].

  23. Walling HW, Messingham M, Myers LM, Mason CL, Strauss JS. Improvement of acanthosis nigricans on isotretinoin and metformin. J Drugs Dermatol. Dec 2003;2(6):677-81. [Medline].

  24. Sherertz EF. Improved acanthosis nigricans with lipodystrophic diabetes during dietary fish oil supplementation. Arch Dermatol. Jul 1988;124(7):1094-6. [Medline].

  25. Romo A, Benavides S. Treatment options in insulin resistance obesity-related acanthosis nigricans. Ann Pharmacother. Jul 2008;42(7):1090-4. [Medline].

  26. Rosenbach A, Ram R. Treatment of Acanthosis nigricans of the axillae using a long-pulsed (5-msec) alexandrite laser. Dermatol Surg. Aug 2004;30(8):1158-60. [Medline].

  27. Ghosh S, Roychowdhury B, Mukhopadhyay S, Chowdhury S. Clearance of acanthosis nigricans associated with insulinoma following surgical resection. QJM. Nov 2008;101(11):899-900. [Medline].

  28. Hud JA Jr, Cohen JB, Wagner JM, Cruz PD Jr. Prevalence and significance of acanthosis nigricans in an adult obese population. Arch Dermatol. Jul 1992;128(7):941-4. [Medline].

  29. Torley D, Bellus GA, Munro CS. Genes, growth factors and acanthosis nigricans. Br J Dermatol. Dec 2002;147(6):1096-101. [Medline].

Previous
Next
 
Brown velvety plaques with skin tags in the axilla of a patient with acanthosis nigricans.
Acanthosis nigricans.
Acanthosis nigricans, obesity related.
Acanthosis nigricans of the axilla with one skin tag.
Acanthosis nigricans biopsy. The epidermis is papillomatous (undulates) and pigmented ("nigricans"). Acanthosis (thickening of the spinous layer) is often not really present, so acanthosis nigricans is often a misnomer in many cases.
Table. Acanthosis Nigricans Associations
Syndromes Associated With Acanthosis NigricansMalignant Diseases Associated With Acanthosis Nigricans
AcromegalyBile duct cancer
Alstrom telangiectasiaBladder cancer
Barter syndromeBreast cancer
Beare-Stevenson syndromeColon cancer
Benign encephalopathyEndometrial cancer
Bloom syndromeEsophageal cancer
Capozucca syndromeGallbladder cancer
Chondrodystrophy with dwarfismHodgkin disease
Costello syndromeKidney cancer
Crouzon syndromeLiver cancer
DermatomyositisLung cancer
Familial pineal body hypertrophyMycosis fungoides
GigantismNon-Hodgkin lymphoma
Hashimoto thyroiditisOvarian cancer
Hirschowitz syndromePancreatic cancer
Lawrence-Moon-Bardet syndromePheochromocytoma
Lawrence-Seip syndromeProstate cancer
Lipoatrophic diabetes mellitusRectal cancer
Lupoid hepatitisTesticular cancer
Lupus erythematosusThyroid cancer
PhenylketonuriaWilms tumor
Pituitary hypogonadism
Pseudoacromegaly
Prader-Willi syndrome
Pyramidal tract degeneration
Rud syndrome
Scleroderma
Stein-Leventhal syndrome
Type A syndrome (HAIR-AN syndrome)
Werner syndrome
Wilson syndrome
Previous
Next
 
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.